Methods for improving cognitive function via modulation of quinone reductase 2
AssigneeCarmel-Haifa University Economic Corp. Ltd.
InventorsKobi Rosenblum, Akiva Rappaport
Life of this patent
Estimating the term…
Abstract
An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
Claims6
A pharmaceutical composition, comprising a shRNA molecule having a sequence corresponding to SEQ ID NO:
- 2, 3 or 4, or a vector comprising said shRNA molecule or a nucleic acid molecule encoding said shRNA molecule, and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising (a) a vector comprising a shRNA molecule having a sequence corresponding to SEQ ID NO:
- 2, 3 or 4 or a nucleic acid molecule encoding said shRNA molecule, and (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.